A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
MoBluRF Enables Sharp 4D Reconstructions from Blurry Video with NeRF
Researchers developed MoBluRF for creating sharp, dynamic 3D neural radiance fields from blurry monocular videos.
•EurekAlert
AI Model Accurately Predicts Post-Surgical Complications from ECGs
An AI model developed by Johns Hopkins significantly outperforms current risk scores in predicting post-surgical complications using routine ECG data.
•EurekAlert
AI Model Predicts Long-Term Disease Risk from Medical Records
A new generative AI model predicts the risk and timing of over 1,000 diseases using large-scale health record data from the UK and Denmark.